See more : PT Global Digital Niaga Tbk (BELI.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Pulse Biosciences, Inc. (PLSE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pulse Biosciences, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Okeanis Eco Tankers Corp. (OKENF) Income Statement Analysis – Financial Results
- Garden City Co. (GCCO) Income Statement Analysis – Financial Results
- Ziff Davis, Inc. (JCOM) Income Statement Analysis – Financial Results
- Huddled Group Plc (HUD.L) Income Statement Analysis – Financial Results
- BELIMO Holding AG (BEAN.SW) Income Statement Analysis – Financial Results
Pulse Biosciences, Inc. (PLSE)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.pulsebiosciences.com
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.21M | 11.94M | 1.97M | 665.00K | 666.00K | 665.00K | 665.00K | 665.00K | 0.00 | 0.00 |
| Gross Profit | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | -665.00K | -665.00K | -665.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -1,606.29% | -38.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.80M | 20.84M | 28.64M | 26.44M | 24.96M | 17.25M | 9.65M | 5.99M | 2.58M | 44.57K |
| General & Administrative | 15.78M | 13.96M | 19.07M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Selling & Marketing | 0.00 | 12.02M | 14.75M | 7.26M | 5.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.78M | 25.97M | 33.82M | 22.86M | 22.33M | 20.05M | 15.50M | 2.93M | 1.22M | 73.71K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 665.00K | 666.00K | -28.00K | 665.00K | 665.00K | 665.39K | 0.00 |
| Operating Expenses | 43.57M | 46.81M | 62.46M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Cost & Expenses | 43.57M | 58.76M | 64.43M | 49.97M | 47.95M | 37.96M | 25.81M | 9.59M | 4.47M | 514.29K |
| Interest Income | 0.00 | 263.00K | 646.00K | 114.00K | 983.00K | 446.00K | 247.00K | 68.00K | 0.00 | 0.00 |
| Interest Expense | 1.36M | 448.00K | 646.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.21M | 1.36M | 1.15M | 1.10M | 1.16M | 1.31M | 1.00M | 759.00K | 716.98K | 200.57K |
| EBITDA | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | -36.65M | -24.57M | -8.83M | -3.75M | -108.00K |
| EBITDA Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | -37.96M | -25.81M | -9.59M | -4.47M | -308.57K |
| Operating Income Ratio | 0.00% | -8,293.86% | -4,443.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.36M | -448.00K | -646.00K | 114.00K | 983.00K | 418.00K | 247.00K | 68.00K | 0.00 | -396.00K |
| Income Before Tax | -42.21M | -58.51M | -63.66M | -49.85M | -46.97M | -37.55M | -25.57M | -9.52M | -4.47M | -514.29K |
| Income Before Tax Ratio | 0.00% | -8,357.86% | -4,489.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 448.00K | -500.00K | -114.00K | -983.00K | -28.00K | -912.00K | -94.00K | -1.66M | 39.43K |
| Net Income | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M | -37.55M | -25.57M | -9.52M | -2.81M | -474.86K |
| Net Income Ratio | 0.00% | -8,421.86% | -4,454.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| EPS Diluted | -0.88 | -1.74 | -2.26 | -2.14 | -2.22 | -2.20 | -1.73 | -0.86 | -0.37 | -0.19 |
| Weighted Avg Shares Out | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
| Weighted Avg Shares Out (Dil) | 48.04M | 33.94M | 27.96M | 23.25M | 20.75M | 17.08M | 14.75M | 11.01M | 7.57M | 2.51M |
Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021....
Pulse Biosciences Announces CE Mark Approval for CellFX® System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced Conformité Européene (CE) mark approval for the CellFX® System. The CE mark confirms that the CellFX...
Pulse Biosciences Grants Equity Incentive Awards To New Employees
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”) a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options covering an...
Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced that a scientific update on its non-thermal NPS mechanism will be featured at the upcoming Controversies and Conversations in Lasers & Cosmetic...
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2020 Results - Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2020 Results - Earnings Call Transcript
Pulse Biosciences Schedules Third Quarter 2020 Financial Results Conference Call for November 9, 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter 2020 after market close on Monday, November 9, 2020. Company management will...
Pulse Biosciences Schedules Second Quarter 2020 Financial Results Conference Call for August 10, 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS™) technology, announced today it will report financial results for the second quarter 2020 after market close on Monday, August 10, 2020. Company management will...
Pulse Biosciences Schedules First Quarter 2020 Financial Results Conference Call for May 11, 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. Company management will host a corresponding conference call...
Pulse Biosciences Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 16, 2020
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, announced today it will report financial results for the fourth quarter and full year 2019 after market close on Monday, March 16, 2020. Company management will host a...
Critical Survey: Pulse Biosciences (NASDAQ:PLSE) versus RA Medical Systems (NASDAQ:RMED)
Pulse Biosciences (NASDAQ:PLSE) and RA Medical Systems (NYSE:RMED) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst...
Source: https://incomestatements.info
Category: Stock Reports